共 220 条
[1]
Schweitzer A(2015)Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 Lancet 386 1546-1555
[2]
Horn J(2014)The global burden of liver disease: the major impact of China HEPATOLOGY 60 2099-2108
[3]
Mikolajczyk RT(2006)Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterol 130 678-686
[4]
Krause G(2010)Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatol 52 886-893
[5]
Ott JJ(2013)Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis Gut 62 760-765
[6]
Wang FS(2004)Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B Hepatol 39 804-810
[7]
Fan JG(2007)Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 45-52
[8]
Zhang Z(2020)Effect of nucleos(t) ide analogue on serum HBsAg level in chronic hepatitis B patients: a 3-years study Biomed Pharmacother 122 109698-561
[9]
Gao B(2012)Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 531-1316
[10]
Wang HY(2018)Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients Aliment Pharm Ther 47 1306-20